Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Equity Ratio (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Equity Ratio for 7 consecutive years, with 0.73 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 0.61% year-over-year to 0.73, compared with a TTM value of 0.73 through Dec 2025, up 0.61%, and an annual FY2025 reading of 0.73, up 0.61% over the prior year.
  • Equity Ratio was 0.73 for Q4 2025 at aTYR PHARMA, down from 0.75 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.95 in Q3 2021 and bottomed at 0.71 in Q3 2024.
  • Average Equity Ratio over 5 years is 0.8, with a median of 0.78 recorded in 2023.
  • The sharpest move saw Equity Ratio increased 23.32% in 2021, then decreased 21.21% in 2022.
  • Year by year, Equity Ratio stood at 0.94 in 2021, then fell by 21.21% to 0.74 in 2022, then increased by 0.76% to 0.75 in 2023, then decreased by 3.82% to 0.72 in 2024, then rose by 0.61% to 0.73 in 2025.
  • Business Quant data shows Equity Ratio for ATYR at 0.73 in Q4 2025, 0.75 in Q3 2025, and 0.74 in Q2 2025.